Cytokinetics公司宣布,与美托洛尔相比,其药物Aficamten能够使NT-proBNP水平降低81%,并在左心房容积指数方面实现显著改善。
Cytokinetics公司宣布,与美托洛尔相比,其药物Aficamten能够使NT-proBNP水平降低81%,并在左心房容积指数方面实现显著改善。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.